Daiichi Sankyo (DSNKY) to Post Earnings on Friday

Daiichi Sankyo (OTCMKTS:DSNKY) is expected to announce its resultson Friday, July 31st. Analysts expect Daiichi Sankyo to post earnings of $0.2608 per share and revenue of $3.3434 billion for the quarter. Daiichi Sankyo has set its FY 2026 guidance at 0.910-0.910 EPS.

Daiichi Sankyo (OTCMKTS:DSNKY) last posted its quarterly earnings data on Monday, May 11th. The company reported $0.15 EPS for the quarter, missing analysts’ consensus estimates of $0.33 by ($0.18). The company had revenue of $3.76 billion for the quarter, compared to analyst estimates of $3.74 billion. Daiichi Sankyo had a net margin of 12.32% and a return on equity of 15.75%. On average, analysts expect Daiichi Sankyo to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Daiichi Sankyo Trading Down 0.3%

Daiichi Sankyo stock opened at $17.01 on Friday. The stock has a 50-day moving average price of $16.40 and a 200 day moving average price of $17.91. Daiichi Sankyo has a 52 week low of $14.98 and a 52 week high of $27.50. The stock has a market cap of $31.69 billion, a PE ratio of 18.10, a P/E/G ratio of 2.97 and a beta of -0.17. The company has a current ratio of 2.42, a quick ratio of 1.64 and a debt-to-equity ratio of 0.18.

Analysts Set New Price Targets

Separately, Zacks Research upgraded shares of Daiichi Sankyo from a “strong sell” rating to a “hold” rating in a report on Tuesday, May 5th. One investment analyst has rated the stock with a Hold rating, According to MarketBeat, the stock has a consensus rating of “Hold”.

About Daiichi Sankyo

Daiichi Sankyo Co, Ltd. is a global, research-driven pharmaceutical company headquartered in Tokyo, Japan. The company was formed through the merger of Daiichi Pharmaceutical and Sankyo in 2005 and focuses on the discovery, development, manufacturing and commercialization of prescription medicines. Its therapeutic priorities include oncology and cardiovascular disease, and it pursues a mix of small molecules, biologics and antibody‑drug conjugates in its development programs.

Daiichi Sankyo is known for building a development portfolio through both internal research and collaborative partnerships.